ArriVent BioPharma, Inc. (AVBP) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of ArriVent BioPharma, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$14.64HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
NVCT
Nuvectis Pharma, Inc.
$20.13HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — AVBP vs NVCT
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)NVCT +176.7% (+40.4%/yr)NVCT compounded faster over this window
AVBP NVCT
AVBP vs NVCT: by the numbers
- •AVBP is the larger company ($682M vs $534M market cap).
Metrics side by side
Valuation
| Metric | AVBP | NVCT |
|---|---|---|
| P/B ratio | 1.86 | 58.82 |
Profitability
| Metric | AVBP | NVCT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -306.61% |
| ROIC | -47.96% | -317.86% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.